Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Men, testosterone and Covid‐19
ID
Groti Antonić, Kristina
(
Author
),
ID
Antonič, Blaž
(
Author
),
ID
Caliber, Monica
(
Author
),
ID
Dhindsa, Sandeep
(
Author
)
PDF - Presentation file,
Download
(621,64 KB)
MD5: A90C92F58D0B3322293E4BB84D0FC396
URL - Source URL, Visit
https://onlinelibrary.wiley.com/doi/10.1111/cen.14952
Image galllery
Abstract
Men have more severe Coronavirus disease 2019 (Covid‐19) outcomes and higher mortality rates than women, and it was suggested that testosterone levels might promote severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and Covid‐19 severity. However, clinical studies have not supported this theory. Studies have consistently shown that serum testosterone concentrations during acute Covid‐19 in men are inversely proportional to the inflammatory cytokines and severity of illness. It is likely that lower testosterone concentrations in this setting are a result of acute Covid‐19 illness on the hypothalamic–pituitary–testicular axis. Clinical trials that attempted to lower testosterone concentrations further or block androgen signaling acutely during Covid‐19 in men did not result in improved Covid‐19 outcomes. Additionally, pre‐existing male hypogonadism, diagnosed before Covid‐19 pandemic, was found to be a risk factor for hospitalization from Covid‐19. In this review, we also discuss the preclinical and mechanistic studies that have evaluated the role of androgens in SARS‐CoV‐2 infection and illness. Finally, long‐term consequences of Covid‐19 on male reproductive health are reviewed. SARS‐CoV‐2 virus is known to infiltrate testis and induce orchitis in men, but it is unclear if Covid‐19 leads to an increase in incidence of male hypogonadism.
Language:
English
Keywords:
Covid‐19
,
hypogonadism
,
SARS‐CoV‐2
,
testes
,
testosterone
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
Str. 56-65
Numbering:
Vol. 100, iss. 1
PID:
20.500.12556/RUL-159131
ISSN on article:
0300-0664
DOI:
10.1111/cen.14952
COBISS.SI-ID:
201676803
Publication date in RUL:
01.07.2024
Views:
264
Downloads:
56
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Clinical endocrinology
Shortened title:
Clin. endocrinol.
Publisher:
Wiley
ISSN:
0300-0664
COBISS.SI-ID:
25230336
Licences
License:
CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:
http://creativecommons.org/licenses/by-nc/4.0/
Description:
A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Secondary language
Language:
Slovenian
Keywords:
COVID-19
,
hipogonadizem
,
SARS-CoV-2
,
moda
,
testosteron
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back